Condition
Obesity
Type 2 Diabetes
Locations
Poland
Start date
21/05/2026
Identifiers
Trial ID NN9838-7910,
NCT number NCT07564414,
Eudract number Not Available
NCT number NCT07564414,
Eudract number Not Available
Summary
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks
Trial Overview:
Treatment
DRUG: Cagrisema
DRUG: Semaglutide
Study type
INTERVENTIONAL
Trial duration
May 21 2026 - Apr 19 2028
Participants
2500
Phase
III
Are you eligible?
Gender
Male and female
Age
18 years and older
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.